// App-Quantinova.ai

: Pre-treatment PSA- progression as a negative prognostic factor in patients using 5-alpha-reductase inhibitors prior to radiotherapy for prostate cancer.

Researchers

Presenter

  • Daniel Taussky

Principal Investigators

  • Julie Piotte

  • Kevin Zorn

  • Marc Zanaty

  • Vimal Krishnan

  • Jean-Paul Bahary

  • Marie-Claude Beauchemin

  • Maroie Barkati

  • Cynthia Menard

  • Guila Delouya

  • Carole Lambert

Medical Centers

  • Department of Radiation Oncology, Centre Hospitalier de lUniversite de Montreal, Montreal University, Montreal, QC, Canada

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved